MSB 0.77% 97.3¢ mesoblast limited

AA, page-3

  1. 2,657 Posts.
    lightbulb Created with Sketch. 1705
    For those who say, quite often, you must run an RCT , blah blah blah - the link will take you to hundreds of examples of accelerated approvals based on merely a surrogate endpoint . (CDER table)

    "No no - it can't be so - you have to run RCT's - I have said so many hundreds of times "

    pity the bureaucrats havent used real world survival data

    https://www.fda.gov/media/151146/download


    Efficacy for pediatric SR aGvHD is proven. It hit its primary endpoint.

    Potency assay data work on the 001 trial to be presented or has been presented.

    Would the board bother to present if they did not have the correct data? They would look extremely foolish if that occurred.

    Big chance for pediatric full approval/ accelerated approval - safety and efficacy not an issue.


    Reg





 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.3¢
Change
-0.008(0.77%)
Mkt cap ! $1.116B
Open High Low Value Volume
98.0¢ 98.5¢ 96.0¢ $4.129M 4.236M

Buyers (Bids)

No. Vol. Price($)
9 15858 97.0¢
 

Sellers (Offers)

Price($) Vol. No.
97.5¢ 193337 19
View Market Depth
Last trade - 14.54pm 26/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.